Serotonin Imbalance May Contribute to Autistic Behavior

A deficiency in the levels of serotonin, a key brain chemical, may lead to the development of certain symptoms of autism, suggests a new animal study.

In particular, low serotonin levels may contribute to a lack of sociability, which is one of the hallmarks of autism spectrum disorder (ASD), reports a group of researchers from the Riken Brain Science Institute in Japan.

In the current study, the researchers discovered that giving young mice with low levels of the brain chemical a serotonin boost during the first three weeks of life led to improved social behavior in adulthood.

They also found that administering serotonin via medicinal means — that is, treating the mice with a selective serotonin reuptake inhibitor (SSRI), a drug commonly used to treat depression — improved the balance of the mice’s response to external stimulus.

“Our work shows that early serotonergic intervention rescues regional excitatory/inhibitory abnormalities in the brain as well as behavioral abnormalities,” said corresponding author Toru Takumi with the Riken Brain Science Institute in Japan.

While the Vanderbilt study focused on hyperserotonemia, or elevated levels of the chemical neurotransmitter, the new Japanese study adds an important new layer of understanding of the role and resultant behavior of serotonin deficiency.

“Although abnormalities in the serotonin system have been thought to be part of the pathophysiology in patients with ASD, the functional impact of serotonin deficiency in ASD was totally unknown,” said Takumi.

Low serotonin levels are tied to mood disorders, such as anxiety and depression, and the neurotransmitter also plays a key role in bodily functions that encompass digestion, sleep, blood clotting and sexual health.

In the current study, the researchers used brain-mapping techniques among the mice to identify abnormal neural activity, leading them to focus on serotonin.

“Because the sensory region was receiving abnormally low serotonin input, we reasoned that giving infant mice serotonin therapy might reduce the imbalance and also rescue some of the behavioral abnormalities,” said first author Nobuhiro Sakai, a fellow researcher at the Riken Brain Science Institute.

To test the sociability of mice that had received SSRI therapy, the researchers exposed them to a cage with an unknown mouse and, alternatively, a cage with no mouse. After receiving SSRI therapy, the ASD-linked mice were more likely to spend time with the unknown mouse, which mirrors behavior of non-ASD mice.

The new study leaves the researchers optimistic about a future serotonin-related therapy. However, they caution that additional studies are needed.

“Our genetic model for ASD is one of many and because the number of genetic mutations associated with ASD is so high, we need to investigate differences and common mechanisms among multiple genetic ASD models,” said Takumi.

“Additionally, before we can administrate SSRIs to patients with ASD, we must study the effects of SSRIs in more detail, especially because adverse effects have been reported in some animal studies,” Takumi added.

Richard Scott is a health care reporter focusing on health policy and public health. Richard keeps tabs on national health trends from his Philadelphia location and is an active member of the Association of Health Care Journalists.

MISSION STATEMENT

Our mission at Vital Updates is to bring you the most up-to-date, most accurate health and medical information – without bias or slant. We strive to be your trusted health resource. We also believe in full-circle health and wellness to help you meet your goals. With that in mind, we share common ownership with businesses that distribute premium-quality supplements, skincare products, and vitamin drinks – all verified by independent third-party facilities. We also work with retailers that share a similar passion for innovation and wellness. We’re very proud to advertise these products on our site.